×

Showdown over Sarepta's muscular dystrophy drug

12:31 PM ET Thu, 5 May 2016

Joe Edelman, Perceptive Advisors CEO, is a Sarepta shareholder and believes the company's experimental drug in clinical trials "eteplirsen" will be approved by the FDA. The drug is proposed to treat Duchenne muscular dystrophy.